Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases

Akdeniz University90 enrolled

Overview

The aim of this study is; detection of interleukin(IL)-38, IL-36 gamma(γ) , IL-17 and matrix metalloproteinase(MMP)-9 levels in gingival crevicular fluid (GCF), saliva and serum samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples were obtained from 90 systemically healthy non-smoker individuals with periodontitis (P, n=30), gingivitis(G, n=30) and healthy periodontium (S, n=30). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine IL-38, IL-36γ, IL-17 and MMP-9 levels in the biological samples.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Mouth Diseases Periodontal Inflammation Periodontal Diseases

Interventions

GCF obtainingDIAGNOSTIC_TEST

GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant

Saliva ObtainingDIAGNOSTIC_TEST

Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant

Serum obtainingDIAGNOSTIC_TEST

Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) * At least twenty permanent teeth in the mouth * Non-smoker * No medication for continuous use * Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months. * Not in pregnancy or lactation period. * For the periodontitis group that has not received periodontal treatment in the last 6 months Exclusion Criteria: * Any oral or systemic disease * Regularly using a systemic medication * During pregnancy or lactation * Received periodontal treatment within the last 6 months. * Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months * Smokers

Outcomes

Primary Outcomes

Levels of Interleukin-38 (pg/ml) in GCF, saliva and serum fluid

Time frame: 24 hours after taking the clinical measurements at the first visit

Levels of Interleukin-36 gamma (pg/ml) in GCF, saliva and serum fluid

Time frame: 24 hours after taking the clinical measurements at the first visit

Secondary Outcomes

Levels of Interleukin-17 (pg/ml) in GCF, saliva and serum fluid

Time frame: 24 hours after taking the clinical measurements at the first visit

Levels of Matrix Metalloproteinase-9 (ng/ml) in GCF, saliva and serum fluid

Time frame: 24 hours after taking the clinical measurements at the first visit

Evaluation of Biomarkers Levels in Gingival Crevicular Fluid, Saliva and Serum for Different Periodontal Diseases

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes